Moderna's mRNA flu shot earns FDA approval after rollercoaster review

Chronological Source Flow
Back

AI Fusion Summary

The FDA has approved Moderna's new mRNA-based flu vaccine, named mFLUSIVA. This specific vaccine is intended for use in adults aged 50 and older. The approval comes after a review process, introducing a new type of flu shot to the market. mFLUSIVA utilizes mRNA technology to target the influenza virus for the designated age group. This development marks a significant step in vaccine technology for adults 50 and up, as confirmed by official reports.
Community Comments
Loading updates...
0